Cyclophosphamide-induced cardiomyopathy in the rat

Area of Science:

• Cardiovascular Toxicology
• Pharmacology
• Oncology

Background:

• Cyclophosphamide is a widely used chemotherapeutic agent.
• Cardiotoxicity is a known side effect of cyclophosphamide treatment.
• Understanding the temporal dynamics of cyclophosphamide-induced cardiotoxicity is crucial for patient management.

Purpose of the Study:

• To investigate the acute and chronic effects of cyclophosphamide on cardiac histology and biochemistry in ACI rats.
• To assess the recovery patterns of cardiac tissue following cyclophosphamide administration.

Main Methods:

• ACI rats were administered three doses of cyclophosphamide (150 mg/kg) with 14-day intervals.
• Histological examination of cardiac tissue was performed.
• Heart weight, DNA, and hydroxyproline content were measured at various time points post-treatment.

Main Results:

• Histologic evidence of cardiomyopathy and vascular changes observed as early as 4 days post-treatment.
• Significant increases in heart weight and DNA content (twofold) by Day 56, with myocardial lymphocyte infiltration.
• Hydroxyproline content increased, indicating fibrosis, which gradually resolved after Day 196.

Conclusions:

• Cyclophosphamide induces both acute and chronic cardiac toxicity in rats.
• Cardiac fibrosis is a significant finding, with a slow but eventual decrease in severity.
• These findings underscore the importance of considering toxicity and recovery timelines when designing chemotherapy regimens.